Skip to Content

MD Anderson Events

Clinical Cancer Prevention 2014 Lecture Series with Dr. Steven M. Lipkin

Clinical Cancer Prevention 2014 Lecture Series with Dr. Steven M. Lipkin


UT MD Anderson Cancer Center
The Department of Clinical Cancer Prevention
CCP Lecture Series 2014

Title: Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of  
colon cancer chemoprevention by alpha-difluoromethylornithine

Speaker:      Steven M. Lipkin, M.D., Ph.D.

Date:          January 14, 2014
12:00p – 1:00p
ACB1.2325 A, B, & C

Date: 1/14/14, 12pm to 1pm
Time: 1/14/14, 12pm to 1pm
Location: ACB1.2325 A, B, & C
Format: Seminar/Conference
CME: 0
Facilitator: Xiangwei Wu, Ph.D.
Speaker: Dr. Steven M. Lipkin, MD, PhD
Speaker Bio: Dr. Steven Lipkin is a physician-scientist who has been performing mechanistic, translational and clinical genetic studies for more than a decade. I have published in many well-cited journals, including Cell, Cell Stem Cell, Nature Biotechnology, Nature Genetics, Science, Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Cancer Discovery, among others. My research program focuses on mechanistic and translational aspects of cancer genetics, particularly for gastrointestinal malignancies. A highlight of my research program that has successfully been clinical translated is the cloning and mechanistic characterization of MutL Homologue 3 (MLH3). MLH3 is a DNA mismatch repair gene that is a Mendelian cause of increased germline colorectal cancer risk and whose mutation is a clinically available genetic test in the US and EU. Mechanistically, my lab also showed that functional redundancy between MLH3 and another DNA mismatch repair gene PMS2 resolved a long-standing paradox observed in clinical cancer genetics: why MLH1 is a common cause of Lynch syndrome while PMS2 and MLH3 are not.
Contact: Dumonique Rayson - (713) 745-1836 -